Antibody to a molecularly-defined antigen confined to a tumour cell surface

No abstract is available for this paper.

• Publication year

  1975

• Venue

  Nature

• Publication date

  1975-04-24

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/254714A0PMID 47617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure and Function of Plasma Proteins

  2012cited by this paper
• Immunisation with Antigen coupled to an Immunosorbent

  1974cited by this paper
• Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes.

  1974cited by this paper
• Recovery of immunoglobulin removed from lymphocytic surfaces by proteolysis.

  1974cited by this paper
• Lymphocytes forming red cell rosettes in the cold in patients with chronic cold agglutinin disease.

  1973cited by this paper
• Syngeneic immune serum specifically inhibits the motility of tumour cells.

  1973cited by this paper
• Studies on antigenic competition. II. Abolition of antigenic competition by antibody against or tolerance to the dominant antigen: a model for antigenic competition.

  1972cited by this paper
• IDIOTYPIC DETERMINANTS OF IMMUNOGLOBULIN M DETECTED ON THE SURFACE OF HUMAN LYMPHOCYTES BY CYTOTOXICITY ASSAYS

  1972cited by this paper
• Myeloma proteins as tumor-specific transplantation antigens.

  1972cited by this paper
• L2C Guinea pig lymphatic leukemia: a "B" cell leukemia.

  1972cited by this paper
• IMMUNOGLOBULINS AS CELL RECEPTORS *

  1971cited by this paper
• Redistribution and pinocytosis of lymphocyte surface immunoglobulin molecules induced by anti-immunoglobulin antibody.

  1971cited by this paper
• REGULATION OF THE IMMUNE RESPONSE: SUPPRESSIVE AND ENHANCING EFFECTS OF PASSIVELY ADMINISTERED ANTIBODY

  1971cited by this paper
• Antigen Recognition Responsible for the Induction In Vitro of the Secondary Response

  1967cited by this paper

• Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial

  2024cites this paper
• First-in-human clinical trial of personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma

  2023cites this paper
• Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol

  2018cites this paper
• RESEARCH ARTICLE A CRITIQUE ON CANCER VACCINE.

  2018cites this paper
• Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

  2017cites this paper
• Cancer vaccines

  2015cites this paper
• Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma

  2014cites this paper
• Towards an off-the-shelf vaccine therapy targeting shared B-cell tumor idiotypes.

  2014cites this paper
• Therapeutic Cancer Vaccines: An Emerging Approach to Cancer Treatment

  2014cites this paper
• Three major uncertainties in the antibody therapy of cancer

  2014cites this paper
• Adoptive T-cell therapy for Leukemia

  2014cites this paper
• Idiotypic Vaccination: Still a Unique form of Cancer Immunotherapy for Follicular Lymphoma after 20 Years

  2013cites this paper
• Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.

  2012cites this paper
• Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients

  2012cites this paper
• lymphoma vaccine immunogenicity and antitumor effects in mice Conjugation of lymphoma idiotype to CD40 antibody enhances

  2012cites this paper
• Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial.

  2012cites this paper
• Identification of human idiotype-specific T cells in lymphoma and myeloma.

  2011cites this paper
• lymphomas: role of immunoregulatory T cells Induction of immunoglobulin secretion in follicular non-Hodgkin's

  2011cites this paper
• derivative of monoclonal anti-idiotype antibody Initial experience in treating human lymphoma with a chimeric univalent

  2011cites this paper
• Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.

  2011cites this paper
• [Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].

  2009cites this paper
• Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity.

  2009cites this paper
• Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures

  2009cites this paper
• Vaccination strategies in follicular lymphoma

  2009cites this paper
• Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials

  2008cites this paper
• Therapeutic Vaccine for Lymphoma

  2007cites this paper
• Lymphomas can develop from B cells chronically helped by idiotype-specific T cells

  2007cites this paper
• Vaccine therapy for B-cell lymphomas: next-generation strategies.

  2007cites this paper
• Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences.

  2007influential citation
• BiovaxID™: a personalized therapeutic cancer vaccine for non-Hodgkin’s lymphoma

  2007cites this paper
• Therapeutic lymphoma vaccines: importance of T-cell immunity

  2006cites this paper
• Personalized immunotherapy for the treatment of non‐Hodgkin's lymphoma: a promising approach

  2006cites this paper
• Treatment of lymphoid tumors with anti-idiotype antibodies

  2005cites this paper
• Immunotherapy of B lymphoma by anti-idiotype antibodies: Characterization of variant tumour cells appearing a long time after the initial tumour inoculation

  2005cites this paper
• Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin’s lymphomas: a focus on FavId™

  2005cites this paper
• Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma

  2005cites this paper
• Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report.

  2005cites this paper
• [Active immunotherapy in the treatment of haematological neoplasias].

  2004cites this paper
• Immunological Approaches to Multiple Myeloma

  2004cites this paper
• DCs in lymphoma--biology and therapeutic aspects.

  2004cites this paper
• Inmunoterapia activa en el tratamiento de neoplasias hematológicas

  2004cites this paper
• Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis

  2004cites this paper
• Attack on neoplastic cell membranes by therapeutic antibody

  2004cites this paper
• Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.

  2004cites this paper
• Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells.

  2004cites this paper
• Idiotype Vaccines in the Treatment of B-Cell Non-Hodgkin's Lymphoma

  2004cites this paper
• Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen

  2004cites this paper
• Non-Hodgkin’s Lymphoma

  2003cites this paper
• Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti‐idiotypic antibody responses

  2002cites this paper
• Cancer vaccines.

  2002cites this paper
• Immunotherapy: On the Edge Between Experimental and Clinical Oncology

  2001cites this paper
• Clinical approaches to vaccination in oncology

  2001cites this paper
• Vacunación idiotípica en linfomas B de bajo grado: una nueva terapia antitumoral

  2001cites this paper
• Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma

  2001cites this paper
• Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intracellular cytokine assay in patients vaccinated with idiotype-KLH vaccine

  2001cites this paper
• Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) Summary of the lecture by L. W. Kwak

  2001cites this paper
• Idiotype Immunity (Natural and Vaccine-induced) in Early Stage Multiple Myeloma

  2000cites this paper
• Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens.

  2000cites this paper
• Idiotypic vaccination as therapy for multiple myeloma.

  1999cites this paper
• Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity

  1999cites this paper
• A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.

  1999cites this paper
• Antitumor Activity IL-12 Bioactivity and Demonstrates Protein Retains Antibody Specificity and A Single-Chain IL-12 IgG3 Antibody Fusion

  1999cites this paper
• Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma

  1999influential citation
• Lymphoma Antigen Induces Potent Protective Cutting Edge: Liposomal Formulation of a Self

  1998influential citation
• Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity.

  1998cites this paper
• Tumor vaccination strategies combined with autologous peripheral stem cell transplantation.

  1998cites this paper
• Development of vaccine strategies for the treatment of B-cell malignancies.

  1997cites this paper
• A Pilot Study of Idiotypic Vaccination for Follicular B-cell Lymphoma Using a Genetic Approach. University of Bristol, Bristol, United Kingdom

  1997cites this paper
• A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.

  1997cites this paper
• Antibody-enzyme conjugates for cancer therapy.

  1996cites this paper
• Induction of humoral and cellular anti-idiotypic immunity by intradermal injection of naked DNA encoding a human variable region gene sequence of an immunoglobulin heavy chain in a B cell malignancy.

  1996cites this paper
• Vaccine strategies in non-Hodgkin's lymphomas.

  1996cites this paper
• [Progress in understanding the development of leukemia. Consequences for the clinic].

  1996cites this paper
• 9 Vaccine strategies in non-Hodgkin's lymphomas

  1996cites this paper
• Idiotypic vaccination against low grade follicular B cell lymphoma

  1996cites this paper
• Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor.

  1995cites this paper
• The current status of human cancer vaccines

  1994cites this paper
• Immunoglobulin idiotype antigen vaccines for the treatment of lymphomas

  1994cites this paper
• Idiotypic IgM on a B-cell surface requires processing for recognition by anti-idiotypic T cells.

  1993cites this paper
• Monoclonal antibodies in cancer detection and therapy.

  1993cites this paper
• A genetic approach to idiotypic vaccination.

  1993cites this paper
• Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

  1992cites this paper
• Immunological techniques in biotechnology research.

  1992cites this paper
• Update on tumor vaccines

  1992cites this paper
• Follicular lymphoma: a model of lymphoid tumor progression in man.

  1991cites this paper
• Characterisation of a light chain loss variant of the BCL1 lymphoma.

  1991cites this paper
• Racial Differences in the Expression of Shared Idiotypes by Paraproteins from Patients with Monoclonal Gammopathies

  1991cites this paper
• Monoclonal Antibodies Raised Against the Idiotype of the Murine B Cell Lymphoma, BCL1 Act Primarily with Heavy Chain Determinants

  1991cites this paper
• NEW APPROACHES TO THE TREATMENT OF FOLLICULAR LYMPHOMA

  1991cites this paper
• Recognition of a B cell lymphoma by anti-idiotypic T cells.

  1990cites this paper
• Expression of shared idiotypes by paraproteins from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

  1990cites this paper
• Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma.

  1990cites this paper
• The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

  1989cites this paper
• Studies of idiotope expression in B-cell chronic lymphocytic leukaemia

  1989cites this paper
• Monoclonal antibodies: A new class of reagents in cancer therapy

  1989cites this paper
• A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge.

  1989cites this paper
• Shared idiotypes expressed by human B-cell lymphomas.

  1989cites this paper
• Use of anti-idiotypic antibodies to treat lymphoid tumors.

  1989cites this paper
• Prospects for the treatment of B cell tumors using idiotypic vaccination.

  1989cites this paper
• Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL1, with different growth characteristics.

  1988cites this paper